FDA authorizes 3rd COVID vaccine dose for immunocompromised individuals

By The Science Advisory Board staff writers

August 13, 2021 -- The U.S. Food and Drug Administration (FDA) has amended the emergency use authorizations for both the Pfizer-BioNTech and Moderna COVID-19 vaccines.

The authorizations now allow for the use of an additional vaccine dose in certain immunocompromised individuals, specifically solid organ transplant recipients or those who have been diagnosed with conditions that place them at an equivalent level of immunocompromise.

Other fully vaccinated individuals currently do not need an additional vaccine dose.

The FDA evaluated information on a third dose of the vaccines in individuals with compromised immune systems and determined that a third dose may increase protection. The administration said these patients should be counseled to maintain physical precautions to help prevent COVID-19.

Close contacts of immunocompromised individuals should get vaccinated to increase protection for this population, according to a statement by the FDA. The agency also recommends that immunocompromised individuals discuss monoclonal antibody treatment options with their healthcare provider should they contract or be exposed to COVID-19.

FDA issues EUA for monoclonal antibody for treatment of hospitalized COVID-19 patients
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) to Genentech, a member of the Roche Group, for tocilizumab...
Moderna files U.S. EUA for COVID-19 vaccine in adolescents
Moderna announced it has requested an emergency use authorization (EUA) from the U.S. Food and Drug Administration for its COVID-19 vaccine in adolescents.
COVID-19 therapies could come from existing drugs
At least four drugs that have already been approved by the U.S. Food and Drug Administration may be effective as COVID-19 therapies, according to a study...
Moderna initiates rolling BLA for COVID-19 vaccine
Moderna has started the rolling submission process with the U.S. Food and Drug Administration for a biologics license application (BLA) for the use of...
FDA issues EUA for GSK-Vir COVID-19 mAb treatment
The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the investigational monoclonal antibody (mAb) therapy sotrovimab...

Copyright © 2021 scienceboard.net

Interphex 2021
October 19-21
New York City, New York United States
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter